

# Highmark, Inc. EPO/PPO

## Commercial HEDIS 2020 Results for Measurement Year 2019

		Measurement Year 2019	Measurement Year 2018	2020 Quality Compass** EPO/PPO National Average
<b>Prevention and Screening</b>				
<b>ABA</b>	<b>Adult BMI Assessment</b>	81.25%	78.60%	69.65%
<b>WCC</b>	<b>Weight Assessment and Counseling for Nutrition and Physical Activity for Children / Adolescent</b>			
	BMI Percentile Total	67.83%	67.83%	59.74%
	Counseling for Nutrition Total	65.09%	65.09%	54.25%
	Counseling for Physical Activity Total	61.35%	61.35%	50.17%
<b>CIS</b>	<b>Childhood Immunization Status</b>			
	Combo 2 - DTaP, Polio, MMR, HepB, Hib + VZV	81.02%	81.02%	71.43%
<b>IMA</b>	<b>Immunizations for Adolescents</b>			
	Meningococcal (MCV4)	84.18%	83.94%	78.28%
	Tdap / Td	87.10%	87.59%	84.05%
	HPV	28.71%	24.09%	27.17%
<b>BCS</b>	<b>Breast Cancer Screening</b>	72.11%	70.73%	71.62%
<b>CCS</b>	<b>Cervical Cancer Screening</b>	72.46%	71.99%	74.18%
<b>COL</b>	<b>Colorectal Cancer Screening</b>	61.60%	61.60%	61.84%
<b>CHL</b>	<b>Chlamydia Screening</b> Combined Rate	45.31%	44.69%	47.20%
<b>Respiratory Conditions</b>				
<b>CWP</b>	<b>Appropriate Testing for Pharyngitis</b> Total <sup>1</sup>	79.51%	ND	75.94%
<b>SPR</b>	<b>Use of Spirometry Testing in the Assessment and Dx of COPD</b>	38.82%	39.38%	39.11%
<b>PCE</b>	<b>Pharmacotherapy Management of COPD Exacerbation</b>			
	Systemic Corticosteroid	88.10%	82.64%	74.03%
	Bronchodilator	86.95%	84.66%	78.96%
<b>MMA</b>	<b>Medication Management for People With Asthma</b>			
	Total Medication Compliance 50%	77.03%	77.06%	ND
	Total Medication Compliance 75%	58.12%	56.00%	56.71%
<b>AMR</b>	<b>Asthma Medication Ratio</b> Total	80.84%	83.03%	78.89%
<b>Cardiovascular Conditions</b>				
<b>CBP</b>	<b>Controlling High Blood Pressure</b>	61.31%	61.31%	47.63%
<b>PBH</b>	<b>Persistence of Beta Blocker Treatment after a Heart Attack</b>	90.36%	84.75%	85.58%
<b>SPC</b>	<b>Statin Therapy for Patients with Cardiovascular Disease</b>			
	Received Statin Therapy - Total	83.79%	82.10%	80.84%
	Statin Adherence 80% - Total	79.27%	78.54%	79.46%
<b>Diabetes</b>				
<b>CDC</b>	<b>Comprehensive Diabetes Care</b>			
	Hemoglobin A1c (HbA1c) Testing	89.67%	89.67%	90.02%
	HbA1c Poor Control (>9.0%)*	34.43%	34.43%	40.13%
	HbA1c Control (<8.0%)	53.28%	53.28%	48.91%
	HbA1c Good Control (<7.0%)	36.01%	36.01%	34.91%
	Diabetic Retinal Eye Exam	49.18%	49.18%	50.27%
	Medical Attention for Nephropathy	87.87%	87.87%	88.66%
	Blood Pressure Control (<140/90 mm Hg)	60.49%	60.49%	51.27%

# Highmark, Inc. EPO/PPO

## Commercial HEDIS 2020 Results for Measurement Year 2019

<b>Diabetes (continued)</b>				
<b>SPD</b>	<b>Statin Therapy for Patients With Diabetes</b>			
	Received Statin Therapy	63.95%	62.83%	62.51%
	Statin Adherence 80%	74.41%	73.43%	73.52%
<b>Behavioral Health</b>				
<b>AMM</b>	<b>Antidepressant Medication Management</b>			
	Acute Phase Treatment	70.89%	68.33%	72.37%
	Continuation Phase Treatment	55.00%	52.21%	56.49%
<b>ADD</b>	<b>Follow-Up Care for Children Prescribed ADHD Medication</b>			
	Initiation Phase	44.68%	49.53%	39.35%
	Continuation/Maintenance Phase	52.53%	59.70%	46.67%
<b>FUH</b>	<b>Follow-up After Hospitalization for Mental Illness</b>			
	30 Days	67.78%	66.81%	65.38%
	7 Days	43.33%	43.04%	43.53%
<b>FUM</b>	<b>Follow-Up After Emergency Dept. Visit for Mental Illness</b>			
	30 Days	60.73%	58.88%	59.52%
	7 Days	43.39%	42.42%	45.28%
<b>FUA</b>	<b>Follow-Up After Emergency Dept. Visit for Alcohol and Other Drug Dependence</b>			
	30 Days Total	12.24%	12.76%	14.22%
	7 Days Total	8.00%	9.01%	10.52%
<b>Overuse/Appropriateness</b>				
<b>URI</b>	<b>Appropriate Treatment for Upper Respiratory Infection</b> <sup>(A higher rate indicates better performance)</sup>			
	Total <sup>1</sup>	77.90%	ND	78.71%
<b>AAB</b>	<b>Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis*</b>			
	Total <sup>1*</sup>	40.22%	36.60%	40.21%
<b>LBP</b>	<b>Use of Imaging Studies for Low Back Pain</b> <sup>(A higher rate indicates better performance)</sup>	77.41%	75.68%	76.18%
<b>HDO</b>	<b>Use of Opioids at High Dosage*</b> <sup>The rate per 1,000 receiving Rx opioids</sup>	5.67%	4.83%	5.79%
<b>UOP</b>	<b>Use of Opioids From Multiple Providers*</b> <sup>The rate per 1,000 receiving Rx opioids</sup>			
	Multiple Prescribers*	17.05%	17.85%	14.57%
	Multiple Pharmacies*	5.21%	5.97%	3.20%
	Multiple Prescribers and Multiple Pharmacies*	3.97%	4.23%	1.54%
<b>Access/Availability of Care</b>				
<b>IET</b>	<b>Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment</b>			
	Initiation Total	40.90%	41.36%	36.35%
	Engagement Total	17.72%	18.55%	13.87%
<b>PPC</b>	<b>Prenatal and Postpartum Care<sup>1</sup></b>			
	Timeliness of Prenatal Care	78.35%	77.31%	74.11%
	Checkups After Delivery	81.75%	74.93%	72.61%
<b>CAHPS®</b>				
<b>FSA</b>	<b>Flu Shots for Adults Ages 18 - 64</b>	54.30%	49.54%	55.74%

ND No data available in Quality Compass® or ND in 2019 due to first year measure; <sup>1</sup> Trending between Measurement Year to Prior Year should be considered with caution due to no data in prior year or change in specifications; \*Lower rates indicate better performance; \*\*National Averages taken from NCQA's Quality Compass® 2020; CAHPS® is a registered trademark of the Agency for Healthcare Research and Quality (AHRQ)